Second dose of experimental drug may help heart amyloidosis patients
NCT ID NCT07213583
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a second round of treatment with ALXN2220 is safe and can improve heart function in people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. About 35 adults who previously received the drug will get it again and be monitored for 48 weeks. The goal is to see if the drug reduces protein buildup and helps the heart work better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID TRANSTHYRETIN CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Toulouse - Hôpital Rangueil
Toulouse, 31059, France
-
CHU de Rennes - Hôpital Pontchaillou
Rennes, 35033, France
-
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, 28222, Spain
-
Hôpital Henri Mondor
Créteil, 94000, France
-
University Medical Center Groningen
Groningen, 9713, Netherlands
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany